ZYME

Over the past six months, Zymeworks' stock has been influenced by several events. The Q1 2026 earnings report showed a revenue decline, but the company maintained a strong cash position. The FDA and China's NMPA accepted sBLAs for zanidatamab. Zymeworks secured a $250 million royalty monetization deal and continued its share repurchase program. The company presented clinical data for ZW191 and preclinical data for a RAS-targeting ADC platform. ZYME shares have increased by 61.6% in the last six months and 135% over the past year.